51
|
Sinha N, Letourneau J, Xiong P, Harris E, Gomes E, Chin-Yu C, Mok-Lin E, Cedars M, Rosen M. Fertility outcomes in reproductive aged breast cancer patients after chemotherapy. Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
52
|
Letourneau J, Sinha N, Harris E, Gomes E, Chin-Yu C, Mok-Lin E, Cakmak H, Cedars M, Rosen M. Back-to-back random start ovarian stimulation prior to chemotherapy results in a doubling of oocyte yield. Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
53
|
Ranger A, Dunlop A, Maclennan M, Donovan E, Harris E, Brigden B, Knowles C, Carr K, Henegan E, Francis J, Bartlett F, Somiah N, Locke I, Coles C, Kirby A. OC-0452: Evaluation of a novel field placement algorithm for tangential internal mammary chain radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30894-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
54
|
Blott H, Bhattacherjee S, Harris E. An evaluation of the use of electroconvulsive therapy in a United Kingdom high secure psychiatric hospital. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.02.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionElectroconvulsive therapy (ECT) is an effective NICE-approved treatment for severe depression, treatment-resistant mania and catatonia; the Royal College of Psychiatrists’ (RCPsych) guidelines also support its use fourth line for treatment-resistant schizophrenia.ObjectivesEvaluate the use of ECT at Broadmoor High Secure psychiatric hospital, focusing on the indications for its prescription and patients’ capacity to consent.MethodAnalyse case records of all patients who received ECT, and of all patients referred for Second Opinion Appointed Doctor (SOAD) certified ECT treatment under Section 58 of the Mental Health Act 1983 (MHA) due to incapacity, between 01.09.11 and 30.07.15.ResultsAll patients lacked capacity to consent to treatment during this time. Thirty-three referrals were made to the SOAD service for 15 patients, and of these 30 resulted in certification (T6) of which 10 were not subsequently used. Improvements in mental state and agreement to take clozapine were common reasons for T6s either not being certified or used. Urgent treatment under Section 62 of the MHA was employed 7 times for 4 patients during this period. Of the referrals to the SOAD service, 25 were for treatment-resistant schizophrenia, 5 for mania, 3 for catatonia and none for depression.ConclusionsThose patients requiring ECT within this population tended to be the most unwell and all lacked the capacity to consent to it. The majority (76%) of patients receiving ECT at Broadmoor do so outside of NICE (but within RCPsych) guidelines. ECT may be an effective strategy for promoting compliance with clozapine.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
55
|
Harris E, Töpf A, Hudson J, Barresi R, Bushby K, Lochmüller H, Straub V. Myofibrillar myopathy phenotype due to recessive mutations in MEGF10. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30242-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
56
|
James M, Mayhew A, Eagle M, Moore U, Muni Lofra R, Hilsden H, Bettinson K, Harris E, Straub V, Bushby K. Development of a robust disease specific functional measure suitable for trials in ambulant and non-ambulant individuals with dysferlinopathy. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30249-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
57
|
Danaher P, Skewis L, Mashadi-Hossein A, Ram N, Gowen-MacDonald J, Harris E, Ferree S, Buckingham W. Abstract P6-07-01: Development of a Prosigna® (PAM50)-based classifier for the selection of advanced triple negative breast cancer (TNBC) patients for treatment with enzalutamide. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Enzalutamide is an orally administered androgen receptor (AR) inhibitor approved by the FDA for use in men with metastatic castrate-resistant prostate cancer. A recent phase II study of enzalutamide in patients with advanced, AR positive, TNBC (NCT01889238) demonstrated significant improvements in both PFS and OS for patients whose tumors exhibited a gene expression (Gx) profile enriched in AR signaling and luminal biology. A PAM50-based signature was developed from the phase 2 study which used next generation RNA sequencing (NGS) to identify patients likely to respond to enzalutamide. We transitioned the test to the NanoString (NS) nCounter® Analysis System using Prosigna reagents to support clinical validation in a phase 3 trial. Here we describe the development and analytical performance of the NanoString Androgen Gene Expression Profiling Assay-1 (NS-AR-01). Methods: The NS-AR-01 algorithm coefficients were calibrated from the Predict AR algorithm by testing FFPE tumor tissue from patients who were pre-screened but not enrolled in the phase II study with both platforms (NGS and NS). Three unique algorithms were developed and subsequently challenged with an independent sample set with NGS data to provide an unbiased evaluation of the concordance of the platforms. A pre-specified clinical accuracy verification study was performed through prediction of NS-AR-01 scores from the NGS Gx data from the patients included in the phase 2 study efficacy analysis. The final NS-AR-01 algorithm was selected based on performance in the clinical accuracy verification. The final NS-AR-01 algorithm was evaluated in the 118 patients included in the ITT analysis, as well as those treated with 0-1 lines of prior therapy. The analytical performance of the assay was characterized by testing precision from RNA, reproducibility from FFPE tissue, sensitivity to RNA input amounts, and the impact of common interferents. Results: All three algorithm translations met the pre-specified clinical accuracy verification acceptance criteria. The final NS-AR-01 algorithm generated a hazard ratio most similar to that observed from the NGS algorithm. The total standard deviation when testing multiple FFPE sections from the same block was < 1.5% of the score range with an empirical concordance rate of 100% for biomarker status. The range of RNA input specified for Prosigna was successfully verified for NS-AR-01 (125ng–500ng total RNA). The assay was demonstrated to be robust to common interferents including non-tumor tissue. Conclusions: Based on these results, NS-AR-01 is an accurate, precise, and robust assay for the identification of advanced TNBC patients who may respond to treatment with enzalutamide. The assay is well suited to clinical applications, and its ability to identify responders to enzalutamide will be evaluated in future investigational studies.Background: Enzalutamide is an orally administered androgen receptor (AR) inhibitor approved by the FDA for use in men with metastatic castrate-resistant prostate cancer. A recent phase II study of enzalutamide in patients with advanced, AR positive, TNBC (NCT01889238) demonstrated significant improvements in both PFS and OS for patients whose tumors exhibited a gene expression (Gx) profile enriched in AR signaling and luminal biology. A PAM50-based signature was developed from the phase 2 study which used next generation RNA sequencing (NGS) to identify patients likely to respond to enzalutamide. We transitioned the test to the NanoString (NS) nCounter® Analysis System using Prosigna reagents to support clinical validation in a phase 3 trial. Here we describe the development and analytical performance of the NanoString Androgen Gene Expression Profiling Assay-1 (NS-AR-01). Methods: The NS-AR-01 algorithm coefficients were calibrated from the Predict AR algorithm by testing FFPE tumor tissue from patients who were pre-screened but not enrolled in the phase II study with both platforms (NGS and NS). Three unique algorithms were developed and subsequently challenged with an independent sample set with NGS data to provide an unbiased evaluation of the concordance of the platforms. A pre-specified clinical accuracy verification study was performed through prediction of NS-AR-01 scores from the NGS Gx data from the patients included in the phase 2 study efficacy analysis. The final NS-AR-01 algorithm was selected based on performance in the clinical accuracy verification. The final NS-AR-01 algorithm was evaluated in the 118 patients included in the ITT analysis, as well as those treated with 0-1 lines of prior therapy. The analytical performance of the assay was characterized by testing precision from RNA, reproducibility from FFPE tissue, sensitivity to RNA input amounts, and the impact of common interferents. Results: All three algorithm translations met the pre-specified clinical accuracy verification acceptance criteria. The final NS-AR-01 algorithm generated a hazard ratio most similar to that observed from the NGS algorithm. The total standard deviation when testing multiple FFPE sections from the same block was < 1.5% of the score range with an empirical concordance rate of 100% for biomarker status. The range of RNA input specified for Prosigna was successfully verified for NS-AR-01 (125ng–500ng total RNA). The assay was demonstrated to be robust to common interferents including non-tumor tissue. Conclusions: Based on these results, NS-AR-01 is an accurate, precise, and robust assay for the identification of advanced TNBC patients who may respond to treatment with enzalutamide. The assay is well suited to clinical applications, and its ability to identify responders to enzalutamide will be evaluated in future investigational studies.
Citation Format: Danaher P, Skewis L, Mashadi-Hossein A, Ram N, Gowen-MacDonald J, Harris E, Ferree S, Buckingham W. Development of a Prosigna® (PAM50)-based classifier for the selection of advanced triple negative breast cancer (TNBC) patients for treatment with enzalutamide [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-01.
Collapse
|
58
|
Moghanaki D, Harris E, Urdaneta A, Williams M, Kapoor P, Yu J, Schutzer M, Chang M, Hagan M. Multiparametric Magnetic Resonance Imaging Guided Salvage Low-Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer—A 15-Year Experience. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
59
|
Kahn J, Kapoor P, Kapoor R, Harris E, Sharma M, Schutzer M, Moghanaki D. Dosimetric Consequences and Acute Toxicity Following Perirectal Hydrogel Spacer Injection During Permanent Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
60
|
Paradas C, Moore U, James M, Mayhew A, Azzabou N, Fernandez Torron R, Reyngoudt H, Smith F, Harris E, Bettinson K, Hilsden H, Jacobs M, Feng J, Cnaan A, Rufibach L, Eagle M, Blamire A, Carlier P, Bushby K. Clinical outcome study for dysferlinopathy: One-year follow-up. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
61
|
Fong F, Snyder R, Haar R, McCoy S, Stover E, Coloma J, Harris E. Bottom-up design of information and communications technology in an era
of transdisciplinary global health & disruptive social
innovation. Ann Glob Health 2016. [DOI: 10.1016/j.aogh.2016.04.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
62
|
Cameron J, Harris E, McEvedy S, Rendell P, Ski C, McLennan S, Prior D, Thompson D. Heart Failure Patients Versus Healthy Controls: Comparison of Cognitive and Prospective Memory Function. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
63
|
Figueroa-Bonaparte S, Hudson J, Barresi R, Polvikoski T, Williams T, Töpf A, Harris E, Hilton-Jones D, Petty R, Willis TA, Longman C, Dougan CF, Parton MJ, Hanna MG, Quinlivan R, Farrugia ME, Guglieri M, Bushby K, Straub V, Lochmüller H, Evangelista T. Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK. J Neurol Neurosurg Psychiatry 2016; 87:680-1. [PMID: 26105173 PMCID: PMC4893144 DOI: 10.1136/jnnp-2015-310362] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 04/16/2015] [Accepted: 05/05/2015] [Indexed: 11/04/2022]
|
64
|
Shanks D, Wang Q, Verran J, Harris E. Book Reviews. Br J Biomed Sci 2016. [DOI: 10.1080/09674845.2010.11730304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
65
|
Horrocks JA, Stapleton S, Guada H, Lloyd C, Harris E, Fastigi M, Berkel J, Stewart K, Gumbs J, Eckert KL. International movements of adult female leatherback turtles in the Caribbean: results from tag recovery data (2002-2013). ENDANGER SPECIES RES 2016. [DOI: 10.3354/esr00718] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
66
|
Harris E, Hudson J, Marsh J, Marini Bettolo C, Neri M, Ferlini A, Bushby K, Lochmüller H, Straub V, Barresi R. A novel STIM1 mutation at p.340 causes tubular aggregate myopathy with miosis without additional features of Stormorken syndrome. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.369] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
67
|
Bertoli M, Topf A, Harris E, Laval S, Sarkozy A, Lochmüller H, Lynch S, Straub V. A novel mutation in PIEZO2 in a family presenting with autosomal dominant myopathy, ptosis, external ophthalmoplegia and distal symphalangism. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
68
|
Mayhew A, James M, Eagle M, Bladen C, Muni Lofra R, Bettinson K, Hilsden H, Harris E, Bushby K, Rufibach L. Preparation of a disease specific functional measure suitable for trials in dysferlinopathy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
69
|
Casey CA, Rasineni K, Harris E. SY14-3ALD VERSUS NALD: DIFFERENTIAL EFFECTS ON ENDOCYTOSIS AND VESICLE TRAFFICKING PROTEIN CONTENT. Alcohol Alcohol 2015. [DOI: 10.1093/alcalc/agv076.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
70
|
O'shea T, Bamber J, Harris E. SU-D-210-05: The Accuracy of Raw and B-Mode Image Data for Ultrasound Speckle Tracking in Radiation Therapy. Med Phys 2015. [DOI: 10.1118/1.4923920] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
71
|
O'shea T, Bamber J, Harris E. MO-DE-210-05: Improved Accuracy of Liver Feature Motion Estimation in B-Mode Ultrasound for Image-Guided Radiation Therapy. Med Phys 2015. [DOI: 10.1118/1.4925367] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
72
|
Su L, O'shea T, Ng SK, Zhang Y, Iordachita I, Wong J, Harris E, Bamber J, Sen HT, Kazanzides P, Bell ML, Ding K. TH-EF-BRB-09: Real-Time Ultrasound Monitoring with Speckle Tracking in Abdominal Stereotactic Body Radiation Therapy. Med Phys 2015. [DOI: 10.1118/1.4926307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
73
|
Harris E, Cox L, Auld M, Johnston L. Visual perception and upper limb function in children with Developmental Coordination Disorder. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
74
|
Fong H, Harris E, Auerswald C. Building transdisciplinary university collaboration to strengthen global
adolescent health. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
75
|
Baggott C, Harris E, Suntharalingam J, Malin A. P95 Non Cf Bronchiectasis. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|